title: Commentary: Guideline for male testosterone therapy: a regulatory perspective.
authors.affiliation: Division of Reproductive and Urologic Products, Center for Drug Evaluation and Research. U.S. Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA. daniel.shames@fda.hhs.gov
authors.forename: Daniel
authors.initials: D
authors.lastname: Shames
authors.forename: Audrey
authors.initials: A
authors.lastname: Gassman
authors.forename: Harry
authors.initials: H
authors.lastname: Handelsman
mesh_terms: D000728:Androgens / Q000627:therapeutic use*; D004704:Endocrinology / Q000592:standards*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D017410:Practice Guidelines as Topic / Q000592:standards*; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D000728:Androgens; D013739:Testosterone